hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06357715, orgStudyIdInfo id: 2021/373/HP, briefTitle: Effectiveness of Neurodynamic Sliding Mobilisation in the "Slump" Position in Relation to the Perceptible Pain Threshold in Asymptomatic People, acronym: SPEAKER 2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-05-09, completionDateStruct date: 2026-05-09, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: University Hospital, Rouen, class: OTHER, descriptionModule briefSummary: According to the French National Health Agency, the use of manual therapy techniques is "possible" \[grade B\] as part of a multimodal combination of treatments for low back pain. These include so-called "neurodynamic" neural mobilisations, which aim in particular to desensitise the pain system and activate descending inhibitory pathways, with effects on pain and function in patients with nerve-related low back pain. Most of the available evidence does not explain the mechanisms involved in neural mobilisation in the slump position. Pain reduction is observed in more areas of the body with sliding techniques than with traction techniques.In this cross-over, randomised controlled trial, we therefore hypothesise that the neurodynamic sliding technique in the slump position acts on mechanisms linked to central pain modulation processes, conditionsModule conditions: Voluntary, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: the second physiotherapist who evaluate the pressure pain, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: "slump"position, interventions name: no" slump" position, outcomesModule primaryOutcomes measure: Difference in pressure at the moment when the volunteer indicates that the sensation of pressure becomes pain, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06357689, orgStudyIdInfo id: REC ID 6, briefTitle: Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-10-24, primaryCompletionDateStruct date: 2023-03-11, completionDateStruct date: 2023-04-29, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, collaborators name: British University In Egypt, descriptionModule briefSummary: Long non-coding RNAs (lncRNAs) play an important role in different types of cancer, including breast cancer, through regulation of gene expression and epigenetic signatures. Genetic variations such as single nucleotide polymorphisms (SNPs) in lncRNAs have been found to be associated with cancer. Our aim was to provide information about the role of LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859, rs4432291 and rs1558535) in breast cancer susceptibility in the Egyptian population., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 417, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Investigating the relationship of the genotypes of each SNP of the LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) with either increased or decreased risk of breast cancer or no effect in the Egyptian population, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and Estrogen receptor, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and Progesterone receptor, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and HER2 status, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and tumor stage, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and tumor grade, secondaryOutcomes measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and lymph node metastasis, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of pharmacy, Ain Shams University, Advanced Biochemisrty Research Lab, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, locations facility: Faculty of Pharmacy, The British University in Egypt, Pharmacology and Biochemistry Research lab, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06357637, orgStudyIdInfo id: 59/2023, briefTitle: Abdominal Circumference Measure in Caesarian Section, acronym: ACirCuS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: CHU Mohammed VI Marrakech, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to evaluate preoperative measures of abdominal circumference in patients admitted for a cesarean section. The main questions it aims to answer are:* Can preoperative abdominal circumference predict patients with difficult spinal anesthesia* Can preoperative abdominal circumference predict the occurrence of maternal hypotension during cesarean section Participants will be examined preoperatively in terms of visibility and palpation of spinous processes, abdominal circumference will be measured in the supine and sitting positions with other clinical parameters. Spinal anesthesia will be performed by the same experienced anesthesiologist with a standardized procedure. The number of skin punctures, needle reorientations, traumatic Cerebrospinal fluid, need for a paramedian approach or failure will be recorded. Maternal blood pressure and vasopressor requirements will also be monitored., conditionsModule conditions: Anesthesia, Spinal, conditions: Cesarean Section, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Measure of abdominal circumference, outcomesModule primaryOutcomes measure: Number of patients with difficult spinal anesthesia, secondaryOutcomes measure: Rate of Maternal hypotension, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Mohammed VI, status: RECRUITING, city: Marrakech, zip: 40000, country: Morocco, contacts name: MERYEM ESSAFTI, MD, role: CONTACT, phone: +212662393700, email: essafti.m@gmail.com, contacts name: MARINA BOKOBA, MD, role: CONTACT, phone: +242065166209, email: marinande00@gmail.com, contacts name: MERYEM ESSAFTI, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: MARINA NDE BOKOBA, MD, role: SUB_INVESTIGATOR, geoPoint lat: 31.63416, lon: -7.99994, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-01-10, uploadDate: 2024-01-23T03:56, filename: Prot_000.pdf, size: 162775, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-04-01, uploadDate: 2024-04-06T11:11, filename: ICF_001.pdf, size: 350456, hasResults: False
protocolSection identificationModule nctId: NCT06357624, orgStudyIdInfo id: Physiotherapy, briefTitle: Effectiveness of Mulligan Mobilization Technique, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-05-30, completionDateStruct date: 2023-05-30, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Karabuk University, class: OTHER, descriptionModule briefSummary: The aim of this study was to investigate the effects of the Mulligan mobilization technique (MMT) on pain intensity, joint position sense (JPS), kinesiophobia, and disability level in individuals with nonspecific neck pain. A total of 34 female individuals with nonspecific neck pain were included in the study. Pain intensity, JPS, kinesiophobia, and disability levels of all participants were evaluated before and after the 3-week intervention. Participants were randomly divided into two groups. In the first group, the participants received MMT by the physiotherapist twice a week for 3 weeks, and self-mobilization techniques as a home exercise program. The second group was trained only self-mobilization techniques., conditionsModule conditions: Neck Pain, conditions: Disability Physical, conditions: Kinesiophobia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 34, type: ACTUAL, armsInterventionsModule interventions name: Mulligan mobilization, interventions name: Self-Mobilization, outcomesModule primaryOutcomes measure: Disability, primaryOutcomes measure: Neck Pain Severity, primaryOutcomes measure: Joint Position Sense, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tarik Ozmen, city: Karabük, country: Turkey, geoPoint lat: 41.20488, lon: 32.62768, hasResults: False
protocolSection identificationModule nctId: NCT06357611, orgStudyIdInfo id: OST1_015, briefTitle: Combination of Two Osteopathic Techniques for the Hamstring's Stretching Capacity in Basketball Female Players, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-09-16, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2024-12-17, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Natália Maria Oliveira Campelo, class: OTHER, descriptionModule briefSummary: It is known that there are studies that prove the effectiveness of muscle energy techniques and the fourth ventricle technique separately, however, information is scarce regarding the combination of the two and their effectiveness in the population. The aim of this randomized controlled study is to compare the immediate effects of the techniques compared to the muscle energy technique alone in female basketball players., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: In order to allocate each participant to an intervention group, each voluntary participation questionnaire was assigned a number. Subsequently, all the numbers of the participants in the sample were randomly distributed among the 3 groups by the principal investigator., primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Simulated technique, interventions name: Muscle energy technique, interventions name: 4th ventricle technique and muscular energy technique, outcomesModule primaryOutcomes measure: Altered range of motion of the hamstring muscles., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Escola Superior de Saúde do Porto, status: RECRUITING, city: Porto, zip: 4200-072, country: Portugal, contacts name: Natália Campelo, role: CONTACT, phone: +35122 206 1000, email: nmc@ess.ipp.pt, contacts name: Natália MO Campelo, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.14961, lon: -8.61099, hasResults: False
protocolSection identificationModule nctId: NCT06357598, orgStudyIdInfo id: QYFYEC2023-95, briefTitle: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer, acronym: PILOT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-18, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: The Affiliated Hospital of Qingdao University, class: OTHER, descriptionModule briefSummary: Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma., conditionsModule conditions: Non-small-cell Lung Cancer (NSCLC), designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab, interventions name: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), interventions name: Carboplatin or Cisplatin, interventions name: Surgery, outcomesModule primaryOutcomes measure: R0 Resection Rate, secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Resectability Rate, secondaryOutcomes measure: Major Pathological Response (MPR) Rate, secondaryOutcomes measure: Rate of grade 3 and higher grade treatment-related adverse events, secondaryOutcomes measure: Progression-Free Survival (PFS), otherOutcomes measure: Pathological Complete Response (pCR) Rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the Affiliated Hospital of Qingdao University, status: RECRUITING, city: Qingdao, state: Shandong, zip: 266000, country: China, contacts name: Zhe Wu, PhD, role: CONTACT, phone: +86 17863934867, email: 17863934867@163.com, geoPoint lat: 36.06488, lon: 120.38042, hasResults: False
protocolSection identificationModule nctId: NCT06357572, orgStudyIdInfo id: ENZ13-2024, briefTitle: Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2024-03-27, completionDateStruct date: 2024-03-27, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Enzyre B.V., class: INDUSTRY, collaborators name: Instytut Hematologii i Transfuzjologii, Warschau, Poland, descriptionModule briefSummary: The goal of this observational study is to assess if the version A of the HemA EnzySystem, a novel portable coagulation testing platform, can be used in patients with hemophilia A treated with Factor VIII Bypassing Agent (FEIBA). The main question\[s\] it aims to answer are:* Can the version A of the HemA EnzySystem can record thrombin generation within a time frame of 60 min in fresh whole blood samples of patients with hemophilia A treated with FEIBA?* Are the TGA results of the version A of the HemA EnzySystem in agreement with the TGA results obtained with conventional methods in fresh non frozen plasma?Participants are asked to fill in a questionnaire regarding their general health and hemophilia treatment. Subsequently, blood will be drawn from the patients before, and at 30, 120, and 240 minutes after FEIBA administration. Whole blood is immediately tested using the Version A HemA EnzySystem, and plasma is generated for testing with the Ceveron s100 (Technoclone). Leftover samples are frozen for later additional coagulation testing., conditionsModule conditions: Hemophilia A With Inhibitor, conditions: Hemophilia A, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 6, type: ACTUAL, armsInterventionsModule interventions name: Thrombin generation assay (EnzySystem HemA version A - whole blood), interventions name: Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma), interventions name: Additional coagulation tests, outcomesModule primaryOutcomes measure: Time between venipuncture and TGA result, secondaryOutcomes measure: Agreement between TGA obtained with the EnzySystem HemA version A and conventional TGA results, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute of Hematology and Blood Transfusion, city: Warsaw, state: Mazowieckie Województwo, country: Poland, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06357559, orgStudyIdInfo id: OCTA in Myopic CNV, briefTitle: OCTA Changes in Choroidal Neovascularization in High Myopia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-09-15, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV.., conditionsModule conditions: Myopic Choroidal Neovascularisation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: OCTA, outcomesModule primaryOutcomes measure: Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06357520, orgStudyIdInfo id: D6970C00005, briefTitle: A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2024-06-06, completionDateStruct date: 2024-06-06, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, descriptionModule briefSummary: The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: Baxdrostat, interventions name: Itraconazole, outcomesModule primaryOutcomes measure: Area Under Plasma Concentration-Time Curve From Time Zero To Infinity (AUCinf), primaryOutcomes measure: Maximum Observed Plasma Drug Concentration (Cmax), secondaryOutcomes measure: Extrapolated Area Under The Curve From Tlast to Infinity (AUCextr), secondaryOutcomes measure: Area Under Plasma Concentration Curve from Time Zero to the Last Quantifiable Concentration (AUClast), secondaryOutcomes measure: Apparent Total Body Clearance (CL/F), secondaryOutcomes measure: Apparent Volume Of Distribution Based On The Terminal Phase (Vz/F), secondaryOutcomes measure: Terminal Elimination Half-life (t1/2λz), secondaryOutcomes measure: Terminal Rate Constant (λz), secondaryOutcomes measure: Mean Residence Time (MRTinf), secondaryOutcomes measure: Time To Reach Maximum Observed Concentration (tmax), secondaryOutcomes measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on Maximum Plasma Concentration (RCmax), secondaryOutcomes measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on AUClast (RAUClast), secondaryOutcomes measure: Ratio of Baxdrostat (Baxdrostat + Itraconazole) to Baxdrostat (Alone) Based on AUCinf (RAUCinf), secondaryOutcomes measure: Number of Participants with Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Research Site, status: RECRUITING, city: Brooklyn, state: Maryland, zip: 21225, country: United States, geoPoint lat: 39.23039, lon: -76.60219, hasResults: False
protocolSection identificationModule nctId: NCT06357507, orgStudyIdInfo id: hayam hamdy, briefTitle: Molecular Characterization of Moraxella Catarrhalis From Pneumonic Children at Pediatric Assiut University Hospital, acronym: Mcatarrhalis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-01, primaryCompletionDateStruct date: 2027-12-01, completionDateStruct date: 2027-12-20, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: moraxella catarrhalis is responsible for respiratory tract infection in children and adults with streptococcus pneumonia and haemophilus influenza.Moraxella catarrhalis is gram negative diplococci, non-motile and non spore bearing bacteria. Until, 1995 it was considered as a non pathogenic respiratory tract flora.This bacteria is an important pathogen and a common cause of both upper and lower respiratory tract infections, pneumonia, sinusitis and conjunctivitis in infants, children and in elderly patients. In adults, M. catarrhalis also causes chronic obstructive pulmonary disease (COPD) and pneumonia. However, it is associated with a number of respiratory infections affecting both children and adults, including laryngitis, bronchitis and pneumonia ., conditionsModule conditions: Respiratory Tract Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 90, type: ESTIMATED, outcomesModule primaryOutcomes measure: isolation of moraxella catarrhalis, secondaryOutcomes measure: detection of virulence genes of moraxella catarrhalis, secondaryOutcomes measure: detetion of antibiotic resistance, eligibilityModule sex: ALL, minimumAge: 1 Month, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False